CYP2C19 loss-of-function carriers have modest benefit from ticagrelor and aspirin following cerebrovascular event: CHANCE-2 Trial
1. Patients carrying the CYP2C19 loss-of-function mutation (C-LOF), who had experienced a minor stroke or transient ischemic attack, experienced a ...